Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EBITDA (2020 - 2025)

RxSight (RXST) has disclosed EBITDA for 6 consecutive years, with -$9.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 45.56% year-over-year to -$9.2 million, compared with a TTM value of -$39.1 million through Dec 2025, down 43.15%, and an annual FY2025 reading of -$39.1 million, down 43.15% over the prior year.
  • EBITDA was -$9.2 million for Q4 2025 at RxSight, up from -$9.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$5.7 million in Q3 2024 and bottomed at -$17.7 million in Q1 2022.
  • Average EBITDA over 5 years is -$11.5 million, with a median of -$12.2 million recorded in 2023.
  • The sharpest move saw EBITDA tumbled 159.84% in 2022, then skyrocketed 55.7% in 2024.
  • Year by year, EBITDA stood at -$15.7 million in 2021, then rose by 1.12% to -$15.6 million in 2022, then soared by 41.4% to -$9.1 million in 2023, then soared by 31.01% to -$6.3 million in 2024, then plummeted by 45.56% to -$9.2 million in 2025.
  • Business Quant data shows EBITDA for RXST at -$9.2 million in Q4 2025, -$9.6 million in Q3 2025, and -$11.9 million in Q2 2025.